Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.

Journal of the American Heart Association - 15 Dec 2020

Metzinger Mark P, Saldanha Suzanne, Gulati Jaskeerat, Patel Kershaw V, El-Ghazali Ayea, Deodhar Sneha, Joshi Parag H, Ayers Colby, Rohatgi Anand

Abstract excerpt

Background Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport, is inversely associated with CHD and may be affected by sex as well as haptoglobin copy number variants among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Apolipoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol Ester Transfer Proteins

Share to Coronary Disease

Share to Double-Blind Method

Share to Haptoglobins

Share to Oxazolidinones

Share to Placebos

Source

Open in PubMed Open full text

Identifiers

PMID: 33263263
DOI: 10.1161/JAHA.120.018136
PMCID: PMC7955402

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.PMID 33263263Read ↗

Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation.Semantic proximity Read ↗

Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein CholesterolSemantic proximity Read ↗

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.Semantic proximity Read ↗

Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

HDL in the 21st Century: A Multifunctional Roadmap for Future HDL ResearchSemantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association studySemantic proximity Read ↗

Novel association between CDKAL1 and cholesterol efflux capacity: Replication after GWAS-based discovery.Semantic proximity Read ↗

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?Semantic proximity Read ↗

A Druggable G Protein Checkpoint in Cholesterol EffluxSemantic proximity Read ↗

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.